A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, in partial fulfillment for the degree of Master of Medicine (Internal Medicine) February 2017 / Introduction: Systemic lupus erythematosus (SLE) is a rare multisystem autoimmune disease which occurs most severely in young females of African descent. Life expectancy is reduced, either directly due to the disease itself or related comorbidities. Aim of study: To determine the prevalence and spectrum of comorbidities in patients with SLE attending the Chris Hani Baragwanath Academic Hospital (CHBAH) Lupus Clinic. Patients and Methods: A retrospective record review of 200 SLE patients attending the CHBAH Lupus Clinic for at least 6 months. Data collected included demographics, clinical and serological evidence of SLE, autoantibody status, treatment modalities and comorbid conditions. The Charlson Comorbidity Index was used to measure the total comorbidity burden. Results: The majority of patients were black females (94%) with a mean age (SD) of 34.6 years (11). Disease duration and American College of Rheumatology (ACR) criteria fulfilled were 7 years and 5 respectively. The median (IQ range) CCI was 1 (0-3). Baseline and cumulative prevalence of one or more comorbidities was 36.5% (95% CI: 29.8-43.6%), and 56.0% (95% CI: 48.8-63.0%), respectively. The most frequent comorbidities were hypertension (HPT) (43.5%), severe infections (29%), tuberculosis (TB) (15%), and HIV infection (9%). Univariate risk factors for serious infection were the number of ACR criteria fulfilled and leucopaenia, while both univariate and multivariate risk factors were anti-Sm antibodies, thrombocytopaenia and the use of immunosuppressive drugs. Risk factors for HPT included age at onset, disease duration, CNS involvement and chloroquine use. Risk factors for TB were disease duration and the use of azathioprine. Protective factors were age of onset, arthritis as a clinical criteria and hypocomplementaemia. Conclusion: In this study of predominantly black females, comorbidities were common but the spectrum differs to those reported in industrialised, Western countries. Infections, both those requiring hospitalisation for intravenous antibiotics, and TB, were amongst the commonest comorbidities, relating to risk factors such as the use of immunosuppressive drugs, autoantibody status and disease duration. Furthermore, despite the high prevalence of HPT, cardiovascular comorbidities were very rare. / MT2017

Background:Various amalgamation diseases which the ESRD patient of may suffer from have already had quite a lot of research to latter stage abroad .Recently, Abroad research find The ESRD patient in carry on extended dialysis can exert an influence or appear melancholy mood to psychological condition their treat .Extended dialysis may influence its medical resource to use or increase mortality.It gradually become to a topic. Objectives¡GThis study explores the prevelance of ESRD with melancholia and finds out if there are any significant difference upon demography status, comorbodities, dialysis therapy, utilization of health care between ESRD with melancholia and without melancholia.As well as we will discuss the risk factors of ESRD patient with melancholia. Methods¡GWe conducted secondary data analysis with admnstrative data of National Health Insurance between 2000, 2002, 2004 and 2006. We firstly seleced the patients diagnosed as ESRD and melancholia, and merged the data set and other related variables.The data was analyzed by Chi-square test, t-test and logistic regression. Result¡GThe prevelance of ESRD with melancholia were 0.47%(2000), 0.73%(2002),1.27%(2004), 1.34%(2008)¡FESRD patients with and without melancholia was significant difference (p < 0.0001) between sex, dialysis therapy, dialysis duration, and the regions of hospital organizations, class of hospital organizations. ESRD patients with and without melancholia was significant difference (p < 0.0001) between age, comorbidities, dialysis duration, outpatient visits and expenditures. Conclusion¡GThe study was benefited by large sample of adminstative data, but there were some limitation of precision of diagnoses and payment issue of health care system, therefore, we strongly suggested further study could be conducted by research questionnaires to make up the weakness of adminstatrative data.

Background: According to 2010 U.S. Renal Data System 2010Annual Data Report, the incidence and prevalence of End-Stage Renal Disease is the worst of the world in Taiwan. Sleep complaints are common in dialysis patients, and impacts negatively on health. It has become highly important issue. Objectives: This study explored the prevalence of ESRD with sleep disorder. We focused on demography status, comorbidities, dialysis therapies and utilization of health care to define the risk factors of disease. Methods: We conducted secondary data analysis with admnstrative data of National Health Insurance between 2000, 2002, 2004 and 2006. We firstly seleced the patients diagnosed as ESRD and Dyssomnia, and merged the data set and other related variables.The data was analyzed by Chi-square test, t-test and logistic regression. Result: The prevalence of ESRD with sleep disorder for the four years were 2.1%¡B2.7%¡B6.4% and 7.3%, respectively. Female patient has higher risk than male .Higher comorbidity score also lead to higher risk, dialysis therapies in hemodialysis/peritoneal were 16.45¡B16.48¡B8.23 and 7.91 in OR. There were significant differences in regions of hospital organizations (northern compared with the eastern, OR were 3.47, 2.73, 1.94 and 2.29, class of hospital organizations (compared with Physician Clinics), there are more cases in Regional Hospitals, except 2006. Outpatient expenses and visits are both positive correlation in all years. Conclusion: The risk factors of suffering sleep disorder in ESRD patients are sex, comorbidities and dialysis therapies. It is a relatively common but frequently unrecognized, therefore, we strongly suggested further study could be conducted by research questionnaires to make up the weakness of adminstatrative data.

Class of 2005 Abstract / Objectives: The purpose of this study was to determine the demographics of co-morbid disorders and drug abuse characteristics of patients admitted to an inpatient facility for detoxification and treatment of chemical dependency to characterize the treatment programs including the psychiatric medication usage and prescribing patterns and to identify differences between men and women. Methods: Criteria inclusion for admittance included a diagnosis of chemical dependence at Sierra Tucson Behavioral Health Hospital during the time of January through June 2004. Patients were admitted to that were diagnosed with a chemical dependency, identified using a past hospital census. Charts of previously discharged patients were obtained from the medical records department of the institution. Specific variables from each chart were extracted for further analysis utilizing a data form. Results: 285 (170 women and 115) men chemically dependent patients that were admitted during the six-month study period. In this patient population there was a high incidence, 76.84%, of co-morbid psychiatric conditions. The most frequently abused drugs in men were alcohol, nicotine, and cocaine. The most frequently abused drugs in women were alcohol, nicotine, and opiates. Men and women were most frequently placed on a librium based alcohol detoxification program, and secondly a buprenorphine based opiate detoxification program. There was statistical significant improvement in the of Beck Depression Inventory scale (BDI), Beck Hopelessness scale (BHS), and Global Assessment Function (GAF) scores at admit and discharge and a downward trend in Clinical Institute Withdrawal Assessment (CIWA) and Clinical Opiate Withdrawal (COW) scores. Implications: There was a high incidence of co-morbid psychiatric conditions such as depression and anxiety that were present in both genders. In men, Attention Deficit and Hyperactivity Disorder/ Attention Deficit Disorder (ADHD/ADD) was an additional common condition observed, while in women eating disorders were observed. The treatments provided led to an overall improvement in GAF, BDI, BHS, CIWA and COW scores indicating effectiveness of the treatment program.

A obesidade grau III ou também chamada obesidade mórbida é uma condição clínica freqüente e que vem apresentado crescimento progressivo, estando associada a elevadas taxas de morbi-mortalidade. Trata-se de uma doença de origem multifatorial, freqüentemente associada a comorbidezes, necessitando uma abordagem terapêutica que propicie redução de peso, melhora das doenças associadas e conseqüente melhora da qualidade de vida. O tratamento convencional deve ser sempre a primeira escolha, principalmente nos casos de inicio recente e sem antecedentes de tratamentos adequados prévios. A taxa de insucesso, contudo, é extremamente elevada, ocorrendo falha em mais de 90% dos casos. O tratamento cirúrgico atualmente é a alternativa com melhores resultados, porém com riscos de complicações a curto, médio e longo prazo, caso não seja realizado um rigoroso acompanhamento clinico, nutricional e psicológico em equipe multidisciplinar experiente. Esta revisão tem por objetivo discorrer sobre as morbidades associadas à obesidade grave, as opções de tratamento convencional e cirúrgico bem como riscos relacionados à persistência de um grande excesso de peso versus risco cirúrgico. / Morbid obesity is a frequent disease with a progressive increase in incidence and associated with high morbid and mortality rates. It is a multifactorial disease, and is usually associated with comorbidities. It is necessary specific treatment to reduce weight, to improve the comorbidities and obtain a better quality of life. The classic treatment, diet and exercise, should be the first choice, especially in cases of recent onset of severe obesity and poor quality previous treatments. Unfortunately, in more than 90% of the patients this kind of treatment will fail. Bariatric surgery is, nowadays, the best option of treatment, but has several risks of complications in the short, medium or long time followup, mostly in patients not followed by a specialized multidisciplinary team. This is a review about morbid obesity, comorbidities, options of treatment and the risks of stay severely obese versus surgical procedures.

A obesidade grau III ou também chamada obesidade mórbida é uma condição clínica freqüente e que vem apresentado crescimento progressivo, estando associada a elevadas taxas de morbi-mortalidade. Trata-se de uma doença de origem multifatorial, freqüentemente associada a comorbidezes, necessitando uma abordagem terapêutica que propicie redução de peso, melhora das doenças associadas e conseqüente melhora da qualidade de vida. O tratamento convencional deve ser sempre a primeira escolha, principalmente nos casos de inicio recente e sem antecedentes de tratamentos adequados prévios. A taxa de insucesso, contudo, é extremamente elevada, ocorrendo falha em mais de 90% dos casos. O tratamento cirúrgico atualmente é a alternativa com melhores resultados, porém com riscos de complicações a curto, médio e longo prazo, caso não seja realizado um rigoroso acompanhamento clinico, nutricional e psicológico em equipe multidisciplinar experiente. Esta revisão tem por objetivo discorrer sobre as morbidades associadas à obesidade grave, as opções de tratamento convencional e cirúrgico bem como riscos relacionados à persistência de um grande excesso de peso versus risco cirúrgico. / Morbid obesity is a frequent disease with a progressive increase in incidence and associated with high morbid and mortality rates. It is a multifactorial disease, and is usually associated with comorbidities. It is necessary specific treatment to reduce weight, to improve the comorbidities and obtain a better quality of life. The classic treatment, diet and exercise, should be the first choice, especially in cases of recent onset of severe obesity and poor quality previous treatments. Unfortunately, in more than 90% of the patients this kind of treatment will fail. Bariatric surgery is, nowadays, the best option of treatment, but has several risks of complications in the short, medium or long time followup, mostly in patients not followed by a specialized multidisciplinary team. This is a review about morbid obesity, comorbidities, options of treatment and the risks of stay severely obese versus surgical procedures.

A obesidade grau III ou também chamada obesidade mórbida é uma condição clínica freqüente e que vem apresentado crescimento progressivo, estando associada a elevadas taxas de morbi-mortalidade. Trata-se de uma doença de origem multifatorial, freqüentemente associada a comorbidezes, necessitando uma abordagem terapêutica que propicie redução de peso, melhora das doenças associadas e conseqüente melhora da qualidade de vida. O tratamento convencional deve ser sempre a primeira escolha, principalmente nos casos de inicio recente e sem antecedentes de tratamentos adequados prévios. A taxa de insucesso, contudo, é extremamente elevada, ocorrendo falha em mais de 90% dos casos. O tratamento cirúrgico atualmente é a alternativa com melhores resultados, porém com riscos de complicações a curto, médio e longo prazo, caso não seja realizado um rigoroso acompanhamento clinico, nutricional e psicológico em equipe multidisciplinar experiente. Esta revisão tem por objetivo discorrer sobre as morbidades associadas à obesidade grave, as opções de tratamento convencional e cirúrgico bem como riscos relacionados à persistência de um grande excesso de peso versus risco cirúrgico. / Morbid obesity is a frequent disease with a progressive increase in incidence and associated with high morbid and mortality rates. It is a multifactorial disease, and is usually associated with comorbidities. It is necessary specific treatment to reduce weight, to improve the comorbidities and obtain a better quality of life. The classic treatment, diet and exercise, should be the first choice, especially in cases of recent onset of severe obesity and poor quality previous treatments. Unfortunately, in more than 90% of the patients this kind of treatment will fail. Bariatric surgery is, nowadays, the best option of treatment, but has several risks of complications in the short, medium or long time followup, mostly in patients not followed by a specialized multidisciplinary team. This is a review about morbid obesity, comorbidities, options of treatment and the risks of stay severely obese versus surgical procedures.

Epilepsia e cefaleia são doenças neurológicas comuns. A epilepsia atinge cerca de 1% da população mundial, enquanto a cefaleia têm prevalência muito mais elevada, ocorrendo em 38-50% das pessoas. As duas condições dividem mecanismos fisiopatogênicos comuns. Relatos de cefaleia em pacientes neuropediátricos com epilepsia correm, mas são pouco estudados devido ao pequeno número de pacientes e dificuldade de diagnóstico de cefaleia nessa população. Nesse estudo avaliamos a prevalência e as características de cefaleia em pacientes com epilepsia focal de início na infância, na idade adulta e após os 50 nos de idade. Foram analisados 167 pacientes com epilepsia focal. Cento e vinte e cinco destes pacientes (74.8%) apresentaram cefaleia. No primeiro grupo, a idade de início da epilepsia variou de 0-17 anos, no segundo de 18-50 anos e no terceiro acima de 50 anos. Para cada paciente entrevistado, foi utilizado um questionário padronizado, verificando a existência de epilepsia e cefaleia, idade de início, frequência, intensidade, classificação e resposta ao tratamento. No nosso estudo, quanto mais precoce o início da epilepsia, maior a chance de do paciente ser refratário e de apresentar cefaleia. Todos os tipos de cefaleia foram mais comuns em pacientes que iniciaram ainda jovens com epilepsia. A cefaleia foi mais comum em mulheres que iniciaram com epilepsia até 50 anos. Após essa idade, a cefaleia em epilepsia foi mais frequentemente observada em pacientes masculinos. Quando a epilepsia iniciou na infância, a cefaleia ocorreu mais frequentemente associada às crises, sendo predominantemente observada no período pós-ictal e ocorrendo mais comumente na região occipital. Esses achados podem sugerir que ocorre maior sobreposição fisiopatológica entre epilepsia e cefaleia quando a epilepsia inicia na infância. No conjunto, nosso estudo demonstrou que a cefaleia observada em epilepsia tem características dependentes da idade de início das crises. Parece ocorrer uma sobreposição de mecanismos de doença entre cefaleia e epilepsia quando a epilepsia inicia na infância. Essa associação é menos observada quando a epilepsia ocorre após os 50 anos de idade, sugerindo diferentes mecanismos fisiopatogênicos para ocorrência da cefaleia em epilepsia, de acordo com a época de início da epilepsia. / Epilepsy and headache are common neurological diseases. Epilepsy affects around 1% of the world population, while headache prevalence is much higher, occurring in 38-50% of people. Both conditions share mutual physiopathogenic mechanisms. Reports of headache in neuropediatric patients with epilepsy occur, but they are poorly studied due to the small number of patients and difficulty of headache diagnosis on this population. This study evaluated the prevalence and characteristics of headache in patients with focal epilepsy of childhood onset, adulthood and after 50 years old. We analyzed 167 patients with focal epilepsy. One hundred twenty five of those patients (74.8%) had headache. In the first group, the age at onset of epilepsy varied between 0-17 years; in the second group, from 18-50 years; and in the third group above 50 years. For each patient interviewed, a standardized survey was used to verify the occurrence of epilepsy and headache, the age at onset, frequency, intensity, classification and response to treatment. In this study, the earlier the onset of headache, the greater the chances of the patient is refractory and to present headache. All kinds of headache were more common in patients who started at a young age with epilepsy. Headache was more common in women who started until 50 years old with epilepsy. After this age, headache in epilepsy was more often observed in male patients. When epilepsy started at childhood, headache occurred more often related to the crises, being predominantly observed during post-ictal period and most commonly occurring in the occipital region. These findings may suggest that physiopathologic superposition between epilepsy and headache occurs more often at childhood. As a whole, the study demonstrated that the headache observed in epilepsy has characteristics dependent on the onset age of crises. There seems to be a superposition of disease mechanisms between headache and epilepsy when epilepsy starts during childhood. This association is less observed when epilepsy occurs after 50 years old, suggesting different physiopathogenic mechanisms for headache occurrence in epilepsy, according to the time of onset of epilepsy.

No description available.

No description available.